The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cardiac safety and efficacy of concomitant liposomal doxorubicin, docetaxel, and trastuzumab as neoadjuvant therapy in HER2-overexpressing breast cancer: A retrospective analysis.
Christine Brunner
No relevant relationships to disclose
Thomas Jaeger
No relevant relationships to disclose
Christoph Suppan
Other Remuneration - Roche
Elisabeth Mueller-Holzner
No relevant relationships to disclose
Zerina Jasarevic
No relevant relationships to disclose
Marija Balic
Other Remuneration - Roche
Georg Goebel
No relevant relationships to disclose
Christian Marth
No relevant relationships to disclose
Herbert Stoeger
Consultant or Advisory Role - Roche; Teva
Honoraria - Roche
Hellmut Samonigg
Consultant or Advisory Role - Teva
Honoraria - Roche
Michael Hubalek
Honoraria - Roche
Alois Lang
Honoraria - Roche